Comparative Pharmacology
Head-to-head clinical analysis: LEVETIRACETAM versus SITAVIG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVETIRACETAM versus SITAVIG.
LEVETIRACETAM vs SITAVIG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levetiracetam's precise mechanism of action is unknown. It binds to synaptic vesicle protein 2A (SV2A), which may modulate neurotransmitter release and reduce neuronal excitability. It also inhibits N-type calcium channels and reduces calcium influx, contributing to antiepileptic effects.
Sitavig (acyclovir) is a synthetic nucleoside analogue that inhibits viral DNA replication. It is phosphorylated to acyclovir triphosphate, which competitively inhibits viral DNA polymerase and incorporation into viral DNA, leading to chain termination.
500-1500 mg PO/IV BID; initial 500 mg BID, titrate by 500 mg BID every 2 weeks as tolerated; maximum 3000 mg/day.
Topical: Apply one 50 mg buccal tablet to the upper gum above the incisor region once daily for 14 days.
None Documented
None Documented
Clinical Note
moderateLevetiracetam + Venlafaxine
"The risk or severity of adverse effects can be increased when Levetiracetam is combined with Venlafaxine."
Clinical Note
moderateLevetiracetam + Nefazodone
"The risk or severity of adverse effects can be increased when Levetiracetam is combined with Nefazodone."
Clinical Note
moderateLevetiracetam + Ranolazine
"The serum concentration of Ranolazine can be increased when it is combined with Levetiracetam."
Clinical Note
moderateLevetiracetam + Stiripentol
6–8 hours in adults; prolonged to 10–11 hours in mild-to-moderate renal impairment (CrCl 30–50 mL/min) and 16–24 hours in severe impairment (CrCl <30 mL/min); neonates up to 16 hours.
Terminal elimination half-life is approximately 20 hours in adults with normal renal function. In patients with renal impairment (CrCl <30 mL/min), half-life increases to up to 40 hours, necessitating dose adjustment.
Primarily renal (66% unchanged, 27% as inactive metabolite); minimal fecal (<2%).
Primarily renal; approximately 80% of the dose is excreted unchanged in urine within 24 hours. Minor fecal excretion (less than 10%).
Category A/B
Category C
Anticonvulsant
Anticonvulsant
"The risk or severity of adverse effects can be increased when Levetiracetam is combined with Stiripentol."